Nationwide study into chlamydia and gonorrhoea Today, the National Institute for Public Health and the Environment (RIVM) launches a nationwide study into chlamydia and gonorrhoea.
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Target group-oriented information more effective in the prevention of skin cancer Avoid sunburn. This is the main advice for the prevention of skin cancer. Targeted information is needed to ensure that people adapt their behaviour accordingly. In places where people are exposed to the sun, for example, or for certain groups of peo
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
Number of STI tests at sexual health centres are rising again In 2021, more than 138,000 people were tested for sexually transmitted infections (STIs) at a centre for sexual health.
More STI tests conducted by Sexual Health Centres In 2021, more people visited a Sexual Health Centre (SHC) to get tested for sexually transmitted infections (STIs) than in 2020. This figure is still lower than in 2019, the year before the coronavirus outbreak.
New criteria for amount of salt, sugar and saturated fat in foods The National Approach to Product Improvement (Nationale Aanpak Productverbetering, in Dutch NAPV) is set to start this year.
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
New: NEVO online 2021 RIVM published a new online edition of the Dutch food composition database (NEVO).
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).